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Abstract
Background: Ampullary cancer is a relatively rare form of cancer and usually treated by pancreatoduodenectomy,
followed by adjuvant therapy. The intestinal subtype is associated with markedly improved prognosis after
resection. At present, only few cell lines are available for in vitro studies of ampullary cancer and they have not
been collectively characterized.
Methods: We characterize five ampullary cancer cell lines by subtype maker expression, epithelial-mesenchymal
transition (EMT) features, growth and invasion, drug sensitivity and response to cancer-associated fibroblast
conditioned medium (CAF-CM).
Results: On the basis of EMT features, subtype marker expression, growth, invasion and drug sensitivity three types
of cell lines could be distinguished: mesenchymal-like, pancreatobiliary-like and intestinal-like. Heterogeneous
effects from the cell lines in response to CAF-CM, such as different growth rates, induction of EMT markers as well
as suppression of intestinal differentiation markers were observed. In addition, proteomic analysis showed a clear
difference in intestinal-like cell line from other cell lines.
Conclusion: Most of the available AMPAC cell lines seem to reflect a poorly differentiated pancreatobiliary or
mesenchymal-like phenotype, which is consistent to their origin. We suggest that the most appropriate cell line
model for intestinal-like AMPAC is the SNU869, while others seem to reflect aggressive AMPAC subtypes.
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Background
Posing a challenge to clinical and pathological assessment
and diagnosis, ampullary adenocarcinoma (AMPAC) in-
volves a wide range of histological differentiation as well
as complex anatomic localization [1, 2]. Besides pancre-
atic, duodenal and distal bile duct adenocarcinomas, the
World Health Organization classification system assesses
AMPAC as one of the tumors of the periampullary region
[3]. In contrast to pancreatic ductal adenocarcinoma
(PDAC) clinicopathological studies indicate favorable sur-
vival prognosis, lower TNM stage and minor lymph node
involvement in AMPAC [1, 4, 5].
Histological differentiation of AMPAC has a strong im-
pact on patient prognosis, as intestinal differentiation is
associated with improved survival in comparison to the
pancreatobiliary subtype [6, 7]. In pathological routine of
hematoxylin-eosin (H&E) staining, difficulties often arise
in regards to precise determination of either intestinal or
pancreatobiliary type. In fact, histologic subtype is not a
black-and-white scale but rather a continuum, in which
tumors exist with mixed differentiation. This has led some
authors to suggest a “forced binary approach” of subtype
assessment [5]. For AMPAC, studies have previously
shown that tumor expressing Cytokeratin 20 (KRT 20)
correlate to intestinal type, while tumor lacking KRT 20
correlate to pancreatobiliary type [8], Caudal type homeo-
box 2 (CDX2) positive staining correlate to intestinal type
[9, 10], and cytokeratin 7 (KRT 7) is expressed in the ma-
jority of pancreatobiliary and a minority of intestinal spec-
imens [11, 12]. Given that there is an existing demand for
the development of further prognostic profiles of AMPAC
differentiation [13, 14], KRT 20, CXD2 and KRT 7 qualify
as potential immunohistochemical markers to determine
survival prognosis [6, 15].
The cellular plasticity phenomenon of epithelial-
mesenchymal transition (EMT) has become an exten-
sively studied biological concept to explain local tumor
invasion and metastasis [16]. Recently, so-called tumor
budding has been interpreted as a clinical correlation for
partial epithelial-mesenchymal transition at the tumor-
stromal interface [17], and has also been previously
shown to be a strong prognostic factor in AMPAC [18].
With recent large scale screening methods to demon-
strate relevant correlations between the in vitro character-
istics in of cell lines and clinical tumor biology [19–22],
there has been increasing interests in cell line panels for
the development of personalized treatment. However, only
few cell lines from human ampullary cancer have been re-
ported thus far, and to our best knowledge, no study has
attempted to characterize these collectively [23–26]. Fur-
thermore, the interaction between AMPAC cells of vary-
ing differentiation and stromal cells, such as cancer
associated fibroblasts (CAF), has yet to be investigated.
This study aims to characterize the five AMPAC cell lines
with respect to subtype, EMT markers and as well as
tumor-stroma interaction.
Methods
Ethics, clinicopathologic assessment and
immunohistochemistry
Ethics board approval was obtained from the institu-
tional ethics board of the University of Freiburg (ref 13/
11). Written informed consent was obtained from pa-
tients for the use of tumor tissue for cell culture experi-
ments. For retrospective histopathologic study, patients
who underwent surgical treatment for AMPAC were
identified from an in-house curated clinical database. A
standard pathology protocol was applied for pancreato-
duodenectomy specimens and clinicopathologic case re-
view were performed as previously described [6]. Only
cases with sufficient formalin-fixed and paraffin-
embedded tissue left for re-assessment were included for
the study. Immunohistochemical staining for KRT7,
KRT20, CDX2, ZEB1 and E-Cadherin was performed as
previously described [6, 27]. Tumor budding was quanti-
fied at the invasive front according to a protocol previ-
ously established from pancreatic cancer [27]. CAF
activation grade was classified according to Ha et al [28]
as high (immature stroma) or low (mature stroma). Ma-
ture tumor stroma was defined as tumor stroma includ-
ing fibroblasts with small spindle cell morphology, a thin
and wavy body-structure and a symmetric/parallel orien-
tation. Immature tumor stroma included fibroblasts with
plump spindle-shaped cell morphology, a prominent nu-
cleus with prominent nucleoli and with randomly a
spatial orientation. Tumor stroma was evaluated in two
fields of twenty fold magnification. A value of more than
50 % immature fibroblasts of all fibroblasts were was
considered as immature tumor stroma phenotype.
Clinical statistics and hierarchical clustering
Data collection and statistical analyses were performed
operating with IBM SPSS Version 21 (SPSS Inc,
Chicago, IL) and MedCalc Version 14 software (Medcalc
bvba, Ostend, Belgium). Precise scaling for the different
variables were expressed as median (and range), categor-
ical parameters (cross-tabulation and percentages), and
survival data (Kaplan-Meier method). For statistical test-
ing, Spearman rank correlation and log rank test were
employed. For hierarchical clustering and generation of
heat-map images, Multi Experiment Viewer (MEV,
www.tm4.org) [29] was used. To generate MEV dataset,
gene or antigen expression levels were expressed as rela-
tive values with the maximum level defined as 100 %,
and samples were named according to tumor subtype
(INT intestinal, PB pancreatobiliary, POOR poorly dif-
ferentiated) or cell line. Upon loading to MEV, gene/row
normalization and hierarchical clustering (HCL) was
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performed [30] and heat-map images of the HCL tree di-
agrams generated for visual interpretation.
Cell culture and treatment with CAF-conditioned medium
Ampullary carcinoma cell lines (MDA-AMP7, AVC1,
RCB1280, SNU478, and SNU869) were obtained from
Prof. Frazier (MDA-AMP7, MD Anderson Cancer
Center, Houston/Texas, USA) [23], Prof. Sorio (AVC1,
Institute of Pathology, University of Verona, Italy) [26],
the RIKEN Cell Bank (RCB1280, http://cell.brc.riken.jp/
en/rcb, Japan) and the Korean Cell Line Bank (SNU478
and SNU869, http://cellbank.snu.ac.kr/english/index.php,
Seoul, South Korea) [31]. PANC1 cells were purchased
from the American Type Culture Collection (ATCC,
www.atcc.org). All cells were cultured at 37 °C in 5 %
CO2 atmosphere in DMEM high glucose medium with
GlutamaX (Life Technologies #10566-032) containing
10 % FBS (Life Technologies Standard FBS #10500-064).
Cancer associated fibroblasts (CAF) were isolated by
Bachem’s outgrowth method [32] from a human ampul-
lary adenocarcinoma (pancreatobiliary subtype) resected
by pancreatoduodenectomy, and cell type and purity
assessed by morphology and immunofluescent staining
for Vimentin and Pan-Cytokeratin as described [17].
CAFs were expanded in 75 cm2 cell culture flasks to
70 % confluence and cryopreserved at -80 °C in standard
freezing medium containing DMSO. Only CAF up to
passage six were used.
For generation of CAF conditioned medium (CAF-
CM), CAFs were grown until 70 % confluence, before
switching to fresh medium (DMEM 10 % FCS) and incu-
bated for 72 h. CAF-CM was then removed from the
CAFs, centrifuged at 1000 rpm for 5 min, sterile filtered
(0.22 μm), and transferred to AMPAC cells, which were
previously seeded in standard culture flasks for one day
prior and washed with PBS. Fresh CAF-CM was added
every three days. AMPAC cells were cultured in CAF-
conditioned medium for 5–7 days until 70 % confluence
and CAF-CM treated and control cells were harvested
by cell scraper after three times rinsing with PBS, centri-
fuged and pelleted at 1000 rpm for 5 min.
Gene expression analysis, cell invasion and growth assay
Immunofluorescence of cultured cells and real time PCR
for measurement of mRNA expression was performed as
previously described [17]. Primer sequences were Actin
beta (ACTB, GCCCTGAGGCACTCTTCCA, TTGCGG
ATGTCCACGTCA) E-Cadherin (CDH1, GTCCTGG
GCAGAGTGAATTT, GACCAAGAAATGGATCTGTG
G), Zinc finger E-box binding homeobox-1 (ZEB1, AAG
AATTCACAGTGGAGAGAAGCCA, CGTTTCTTGCA
GTTTGGGCATT), Caudal type homeobox 2 (CDX2, C
TGGAGCTGGAGAAGGAGTTTC, ATTTTAACCTGC
CTCTCAGAGAGC), Cytokeratin 7 (KRT7, TGCTG
AAGAAGGATGTGGATGCTGC, TCTGGGACTGCAG
CTCTGTCAACT) and Cytokeratin 20 (KRT20, GCG
ACTACAGTGCATATTACAGACAA, GCAGGACAC
ACCGAGCATTT). Cultrex BME Cell Invasion Assay
(Trevigen #3465-096-K) was performed according to the
manufacturer’s instructions as described [33]. For assess-
ment of CAF effect on AMPAC cell invasiveness, CAF
were seeded in the lower chamber in standard culture
medium and left until 70 % confluent after 3–6 days,
while control wells contained no CAFs. AMPAC cells
were then seeded into the upper chamber wells in
DMEM medium with 0.1 % FBS and matrigel transmi-
gration measured after three days. Cell growth was
measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay as described [33].
For growth inhibition, low-dose Gemcitabine 40nM (Eli
Lilly Co, Indianapolis, USA) was added to the culture
medium one day after seeding 1000 cells per well into
96 well standard culture plates, and cell growth quanti-
fied after three days of treatment. Herein the pancreatic
cancer cell line PANC1 served as a Gemcitabine-
resistant model [34]. Similarly, all cells were incubated
in Gemcitabine (100 nM, 1 μM or 10 μM) one day after
seeding 20 000 cells per well into 24 well standard cul-
ture plates, and cell growth quantified after three days of
treatment.
Quantitative proteome comparison
Cell pellets from harvesting were lysed using buffer con-
taining 20 mM Tris, pH 7.5, 150 mM NaCl, 1 % (v/v)
Triton X-100 in the presence of protease inhibitors pro-
tease inhibitors (5 mM ethylene diamine tetraacetic acid,
10 μM (2S, 3S)-trans-epoxysuccinyl-L-leucylamido-3-
methylbutane ethyl ester, 1 mM phenylmethanesulfonyl
fluoride). Lysates were kept on ice for 30 min with inter-
mittent inverting to ensure proper lysis. Lysates were
centrifuged for 10 min at 16 000 × g and 4 °C. Protein
concentration of lysates was determined using bicincho-
ninic acid assay. Proteins were precipitated using ice-
cold acetone and trypsinized (Worthington Biochemical
Corp., Lakewood, NJ, USA). Cysteine residues were re-
duced and alkylated, followed by dimethylation of pep-
tide N-termini and lysine residues. Samples from control
treated cells were isotopically labeled using 40 mM
12COH2 formaldehyde (Sigma-Aldrich, Steinheim,
Germany) while samples from fibroblast conditioned
medium were isotopically labeled using 40 mM 13COD2
formaldehyle (Cambridge Isotope Laboratories, Andover,
MA, USA) [35, 36], both in the presence of 40 mM so-
dium cyanoborohydride for 16 h at room temperature.
Excess formaldehyde was quenched using 20 mM gly-
cine. Samples were combined in a 1:1 (w/w) ratio man-
ner and desalted using a reversed phase C18 Sep-Pak
SPE column (Waters, Milford, MA, USA). Samples were
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subsequently fractionated using high performance liquid
chromatography, coupled to a strong cation exchange
column (PolyLC, Columbia, MD, USA). Buffer A con-
sisted of 5 mM KH2PO4 and 25 % (v/v) acetonitrile
(pH 2.7), and buffer B consisted of 5 mM KH2PO, 1 M
KCl, and 25 % acetonitrile (pH 2.7). Peptides were eluted
in a linear gradient with increasing concentration of buf-
fer B. Resulting fractions were collected, desalted using
self-packed C18 STAGE tips (Empore, St. Paul, MN,
USA) [37], and analyzed by mass spectrometry.
Mass spectrometry and data processing
Samples were analyzed on an Orbitrap XL (Thermo
Scientific, Bremen, Germany) or an Orbitrap Q-Exactive
plus (Thermo Scientific) mass spectrometer. The Orbi-
trap XL was coupled to an Ultimate3000 micro pump
(Thermo Scientific). Buffer A was 0.5 % (v/v) acetic acid,
buffer B 0.5 % (v/v) acetic acid in 80 % acetonitrile
(HPLC grade). Liquid phases were applied at a flow rate
of 300 nl/min with an increasing gradient of organic
solvent for peptide separation. Reprosil-Pur 120 ODS-3
(Dr. Maisch) was used to pack column tips of 75 μm
inner diameter and 11 cm length. The MS was operated
in data dependent mode and each MS scan was followed
by a maximum of five MS/MS scans. The Q-Exactive
plus mass spectrometer was coupled to an Easy nanoLC
1000 (Thermo Scientific) with a flow rate of 300 nl/min.
Buffer A was 0.5 % formic acid, and buffer B was 0.5 %
(v/v) formic acid in acetonitrile (water and acetonitrile
were at least HPLC gradient grade quality). A gradient
of increasing organic proportion was used for peptide
separation (5–40 % (v/v) acetonitrile in 80 min). The
analytical column was an Acclaim PepMap column
(Thermo Scientific), 2 μm particle size, 100 Å pore size,
length 150 mm, inner diameter 50 μm. The mass spec-
trometer operated in data dependent acquisition mode
with a top ten method at a mass range of 300–2000 Da.
LC-MS/MS data were analyzed using X! Tandem (Ver-
sion 2013.09.01) [38] in conjunction with PeptideProphet
[39] using a 5 % peptide false discovery rate and a decoy
search strategy, and ProteinProphet [40] at a protein false
discovery rate of 1 %. The protein database was composed
of annotated human UniProt protein sequences (without
isoforms, downloaded on on November 26, 2013 with
20,240 real protein entries), combined with a randomized
and a reversed decoy database X! Tandem parameters in-
cluded: precursor mass error of ± 10 ppm, fragment ion
mass tolerance of 20 ppm (Q-Exactive) or 0.4 Da
(Orbitrap XL), tryptic specificity with no missed cleavage,
static residue modifications: cysteine carbamidomethyla-
tion (+57.02 Da), as well as lysine and N-terminal
dimethylation (12COH2 formaldehyde, +28.03 Da;
13COD2
formaldehyde, +34.06 Da). For relative peptide and protein
quantification, XPRESS [41] was used. Mass tolerance for
quantification was ± 0.015 Da (for Orbitrap XL), or ±
20 ppm (for Q-Exactive Plus). Ratios of each dataset were
calculated as treated cells over control. The mass spec-
trometry proteomics data have been deposited to the Pro-
teomeXchange Consortium [42] via the PRIDE partner
repository with the dataset identifier PXD002657 (user-
name: reviewer66711@ebi.ac.uk password: TdyZ2Yle).
XPRESS data was log2 transformed, resulting in fold-
change values. Proteins were considered as being differen-
tially regulated if the proteins are consistently expressed
minimum three out of five cell lines with a fold-change
value of greater than 0.58 (differential abundance equiva-
lent to 50 %). The list of affected proteins was submitted
to STRING database version 9.1 [43]. Predicted functional
connections among proteins are based on the following
criteria: neighborhood, co-expression, gene fusion, experi-
ments, co-occurrence, databases and text-mining. QIA-
GEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN
Redwood City, www.qiagen.com/ingenuity) was further
used to derive and visualize biological themes that were
significantly associated to affected proteins identified from
mass spectrometry analyses.
Results
Clinical survival analysis and biologic correlation
Clinicopathologic review resulted in the inclusion of
n = 39 patients (17 women, 22 men) treated by pan-
creatoduodenectomy for AMPAC from 2001 to 2011.
Median tumor size was 20 mm, about half of tumors
were of T1/T2 stage and 59 % had locoregional
lymph node metastasis, with a lymph node ratio of
0.10 or more in 44 %. Most tumors displayed low
grading (78 % G1 or G2), microscopic lymphangiosis
was common (49 %), perineural invasion found in
only 33 %, and hemangiosis rare (5 %). There were
only three cases with positive surgical resection mar-
gin (Table 1).
Using a forced-binary approach [5], histopathological
subtypes found were intestinal (46 %), pancreatobiliary
(44 %) and poorly differentiated (10 %). At a median
follow-up of 27 months, only 13 patients had died and
median survival was not reached, giving a mean survival
estimate of 74 months. Patients with positive surgical
margin status suffered poor prognosis (median survival
eight months, p = 0.000). Biological factors that showed
significant prognostic impact (p < 0.05) include intestinal
subtype, lymph node radio and lymphangiosis. Correl-
ation analysis between these prognostic factors disclosed
a negative correlation between intestinal subtype and
lymph node ratio, and a positive correlation of lymphan-
giosis with lymph node ratio (Table 2).
To further assess the biology of the intestinal differenti-
ation, immunohistochemical staining was performed for
KRT 7, KRT 20 and CDX2 for confirmation of phenotype,
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as well as E-Cadherin and ZEB1 for assessment of
epithelial-mesenchymal transition (EMT) (Fig. 1). Tumor
stroma was assessed by morphologic CAF activity grading.
In agreement with previous reports, our results show high
KRT7 and E-Cadherin expressions, low CDX2 and KRT20
expressions, and occasional ZEB1 and Vimentin expres-
sions in the non-intestinal subtypes (pancreatobiliary and
poorly differentiated). In contrast to Vimentin, the vari-
ation in ZEB1 expression level were rather high. In
addition, tumor budding and CAF grade are elevated in
pancreatobiliary type cancers. Furthermore, intestinal type
tumors showed significantly reduced ZEB1 expression in
tumor cells, higher tumor budding at the invasive front as
well as reduced CAF activation grade compared to non-
intestinal tumors (Table 3) (Fig. 2a and b). This has led us
to investigate the interaction between CAF and tumor
cells in vitro to evaluate causality of these associations.
Culture and characterization of ampullary cancer cell lines
and CAF
CAFs were isolated from a human ampullary cancer ex-
plant using Bachem’s outgrowth method [32]. Cell type
and purity was confirmed by typical morphology using
phase-contrast microscopy, in which strong vimentin ex-
pression and lack of Pan-Cytokeratin staining in im-
munofluorescence were observed (Fig. 3). Literature
review revealed eight reported cell lines derived from
AMPAC (Table 4): two cell lines were derived from dis-
tant metastases (MDA-AMP7 and RCB1280), one cell
line from a poorly differentiated primary tumor with sig-
net ring cell features (SNU478), and one from a moder-
ately differentiated AMPAC arising in a villous adeoma
(AVC1). Therefore most cell lines stem from tumors
with aggressive biological features, leaving only one
cell line derived from a well-differentiated AMPAC
(SNU869). At present, no information on AMPAC
subtype or patient follow-up has been reported. One
cell line already ceased (UKEAC-99, personal commu-
nication with author), and the rest was obtained from
the cell line banks or authors (see methods). Five of
seven cell lines were successfully cultured in standard
culture medium (DMEM 10 % FCS) and are used for
further experiments. Three cell lines (RCB1280,
RCB1281, RCB1282) are derived from the same pa-
tient, indicating successful culture of one cell line
from each reported patient.
The ampullary adenocarcinoma cell lines MDA-
AMP7, AVC1, RCB1280, SNU478 and SNU869 were
grown in standard culture medium and expression of
KRT7, KRT20, CDX2, E-Cadherin and ZEB1 mRNA was
measured by real-time PCR. To investigate the heteroge-
neous expression pattern, we employed unsupervised
hierarchical clustering for analysis. Results evidently in-
dicate that three types of expression patterns (Fig. 4a):
Cell lines MDA-AMP7, AVC1, RCB1280 displayed an
undifferentiated mesenchymal-like expression pattern,
characterized by strong expression of the EMT-inducer
ZEB1 and low or lacking expression of E-Cadherin and
subtype markers KRT7, KRT20 and CDX2. The SNU478
Table 2 Correlation matrix for prognostic factors in ampullary
adenocarcinoma
INT PB LNR L R
INT CC -0.81 -0.59 -0.18 -0.27
p .000 .000 .267 .100
PB CC -0.81 0.48 0.07 0.33
p .000 .002 .653 .041
LNR CC -0.59 0.48 0.52 0.21
p .000 .002 .001 .194
L CC -0.18 0.07 0.52 0.30
p .267 .653 .001 .067
R CC -0.27 0.33 0.21 0.30
p .100 .041 .194 .067
CC and p values derived from two-sided Spearman rank correlation
Abbreviations: CC correlation coefficient, INT intestinal subtype, PB
pancreatobiliary subtype, LNR lymph node ratio, L lymphangiosis, R margin
positive resection
Table 1 Baseline parameters
Parameter Condition n or median % or range p-value
n 39 100 % -
Age (years) 64 36–84 0.063a
Sex Female 17 44 % 0.918
Male 22 56 %
Death during follow-up 13 33 % -
Follow-up (months) 27 1–116 -
Tumor size (mm) 20 2–320 0.497
T stage T1/2 19 49 % 0.140
T3/4 20 51 %
Lymph node metastasis 23 59 % 0.112
Lymph node ratio > = 0.10 17 44 % 0.003
Lymphangiosis 19 49 % 0.006
Hemangiosis 2 5 % 0.778
Perineural invasion 13 33 % 0.407
Tumor grade G1-2 28 72 % 0.439
G3-4 11 28 %
Positive margin 3 8 % 0.000
Subtype INT 18 46 % 0.030b
PB 17 44 %
POOR 4 10 %
p values derived from two-sided Logrank test. acutoff at median, btest for INT
vs non-INT subtype
Abbreviations: INT intestinal subtype, PB pancreatobiliary subtype, POOR poorly
differentiated adenocarcinoma
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cells exhibited a pancreatobiliary-like expression pattern
with strong KRT7 and low KRT20 and CDX2 expres-
sion, while the SNU869 cell line showed an intestinal-
like expression pattern with strong KRT20 and CDX2,
but no KRT7 expression. The latter two cell lines also
displayed no or weak expression of the EMT-inducer
ZEB1. Interestingly, intestinal-like SNU869 cells is the
only cell line to express high amounts of E-Cadherin.
To compare the gene expression pattern of cell lines to
the expression pattern in the human AMPAC tumor sam-
ples, maximum gene expression was defined as 100 % and
relative expression values calculated on a linear scale for
each gene. Upon analysis of the relative expression data-
sets of tumors and cell lines, unsupervised hierarchical
clustering revealed two main clusters; intestinal type tu-
mors and pancreatobiliary, respectively (Fig. 4b). Poorly
differentiated tumors did not form a distinct cluster, but
were found as a sub-cluster of the pancreatobiliary type
tumor. Additionally, there was a minor cluster of appar-
ently atypical expression pattern tumors, consisting of
three morphologically intestinal-type and two poorly dif-
ferentiated tumors and characterized by strong CDX2
Table 3 Tumor biologic factors correlating with the intestinal subtype
Parameter Subtype Correlation with INT
INT PB POOR CC p
CK7 % 70 (0–100) 90 (5–100) 40 (0–90) -0.24 0.148
CK20 % 90 (0–100) 5 (0–100) 2.5 (0–10) 0.47 0.003
CDX2 % 90 (20–100) 10 (0–80) 45 (0–100) 0.69 0.000
ZEB1 % 0 (0–2) 0 (0–16) 2 (0–3) -0.32 0.046
VIM % 0 (0–10) 0 (0–10) 0 (0–0) 0.02 0.914
ECad % 100 (50–100) 100 (75–100) 75 (50–100) 0.03 0.869
Budding 8 (0–35) 15 (2–46) 43 (6–66) -0.46 0.003
CAF 1 (0–2) 2 (0–2) 0.5 (0–1) -0.34 0.035
CC and p values derived from two-sided Spearman rank correlation. % expression in percentage of tumor cells, Tumor budding measured as number of tumor
buds per HPF (high power field)
Abbreviations: INT intestinal, PB pancreatobiliary, POOR poorly differentiated, CC correlation coefficient, KRT cytokeratin staining, CDX2 caudal type homeobox 2,
ZEB1 zinc finger and homeobox 1, ECad E-Cadherin, CAF cancer associated fibroblast activation
Fig. 1 Immunohistochemical staining of ampullary cancer. Subtype (a-d; g-j) and EMT (e&f; k&l) histomorphologoical and immunohistological
analysis for the intestinal (a-f) and pancreatobiliary (g-l) AMPAC subtype, taken at 40-fold magnification. HE (a&g) staining representing the
pancreaticobilliary (a) subtype with cuboidal formed columnar tumor cells and rounded nuclei, membranous KRT7 (c) positivity, CDX2 (b) and
KRT20 (d) negativity and the intestinal type (g) with pseudostratified mucin producing glandular epithelium, elongated hyperchromatic and
pseudostratified nuclei, nuclear CDX2 (h) and membranous KRT20 (j) positivity and KRT7 negativity (i). Nuclear ZEB1 expression (e, red arrows) is
linked with a immunohistological membranous to cytoplasmatic Ecad shuttling. Contrary absent ZEB1 expression is immunohistological
accompanied with membranous Ecad expression. Abbreviation: EMT Epithelial-Mesenchymal-Transition; AMPAC Ampullary Adenocarcinoma; HE
Hematoxylin-Eosin, KRT Cytokeratin, CDX2 Caudal Type Homeobox 2, ZEB1 Zinc finger E-box binding homeobox 1, Ecad E-Cadherin
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expression but no KRT20 or KRT2 expression. In regards
to the cell lines, the mesenchymal-like cell lines MDA-
AMP7, AVC1 and RCB1280 clustered together with a
poorly differentiated tumor in the pancreatobiliary cluster,
while being closely related to the pancreatobiliary-like
SNU478 cell line together with a pancreatobiliary tumor.
The intestinal-like cell line SNU869 however was found
within the cluster for intestinal tumor, a clear separation
from the other cell lines.
In vitro growth, invasion and chemosensitivity
Following above-mentioned observations, we hypothe-
sized that cell invasion in vitro would reflect the clinical
tumor aggressiveness. Baseline cell growth assessed by
MTT assay demonstrated that SNU869 cells were the
slowest growing among all AMPAC cell lines (Fig. 5a).
Also the matrigel transmigration assay confirmed that
the mesenchymal-like cell lines had the strongest inva-
sion, followed by the pancreatobiliary-like SNU 478,
while the intestinal-like SNU869 cells were far less inva-
sive (Fig. 6a). Low-dose Gemcitabine, a commonly used
drug for adjuvant AMPAC treatment [44], significantly
inhibited the growth of the mesenchymal- and
pancreatobiliary-like AMPAC cells, but not of the
intestinal-like cell line, where cell growth was even
slightly increased after three days. As a control, growth
of PANC1, a pancreatic cancer cell line known to be
Gemcitabine resistant [34], was not changed (Fig. 5b).
Cell viability of all cell lines in response to higher con-
centrations of Gemcitabine is also highlighted (Fig. 5d).
Effects of CAF-conditioned medium on ampullary cancer
cells
Given the clinical association of high CAF activation grade
in the more aggressive tumors with pancreatobiliary differ-
entiation and EMT features, we further hypothesized that
CAF could induce EMT and invasion, as well as subtype
shift in cancer cells. To examine the paracrine effect of
CAF, ampullary cancer cells were treated with conditioned
medium from CAF (CAF-CM) and subjected to growth
assay as well as matrigel transmigration assay with CAFs
serving as attractant (Fig. 6b and c).
Fig. 3 Cancer associated fibroblasts isolated from ampullary cancer. Cancer associated fibroblasts (CAF) were isolated from human ampullary
cancer by the outgrowth method. Immunofluorescent staining confirms strong expression of Vimentin (VIM) and typical spindle-like morphology,
as well as lack of Pan-Cytokeratin (PanCK) staining
Fig. 2 CAF activation grade in AMPAC, represented by HE staining taken
at 40-fold magnification. a Immature tumor stroma with plump spindle-
shaped cell morphology, prominent nucleus, prominent nucleoli (red
arrow) and with randomly a spatial orientation. b Mature tumor stroma
with small spindle cell morphology, a thin and wavy body-structure
(blue arrow) and a symmetric/parallel orientation. Abbreviation: AMPAC
=Ampullary Adenocarcinoma; HE =Hematoxylin-Eosin
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In the intestinal-like cell line SNU869, ZEB1 levels
remained unchanged but E-Cadherin expression levels
were reduced by approximately 50 %, while cell growth
and invasion increased by about 50 % with CAF-CM
treatment (Figs. 5b and 6b). The pancreatobiliary-like
cell line SNU478 did not express significant changes in
level of ZEB1 or E-Cadherin. However, a decrease of
matrigel transmigration and no change in growth
(Figs. 5b and 6b) were observed in SNU478 cells. Re-
garding the expression of the subtype marker genes, a
Fig. 4 Heatmaps and hierarchical clustering trees of ampullary cancer cell lines and tumors. Relative expression values of EMT (ZEB1, CDH1) and
subtype marker genes (KRT7, KRT20, CDX2) were calculated by linear scaling, with maximum expression in cell lines/tumors defined as 100 % and
subjected to hierarchical clustering (HCL). a HCL tree of the cell lines discloses an mesenchymal-like (MES) and a differentiated (D) cluster of cell
lines. MES cells show weak or no expression of subtype marker genes but strong ZEB1 and low E-Cadherin (CDH1) expression. One differentiated
cell line displays pancreatobiliary-like (SNU478, orange), the other an intestinal-like marker gene expression pattern (SNU869, blue). b HCL tree of
tumors and cell lines results in separation of an intestinal (INT), pancreatobiliary (PB) and atypical (AT) cluster. The cell lines are found separated to
the PB and INT clusters. For further details see text. Abbreviations: EMT epithelial-mesenchymal transition, ZEB1 zinc finger E-box binding homeobox 1,
CDH1 Cadherin 1 = E-Cadherin, KRT Cytokeratin, CDX2 Caudal type homeobox 2, POOR poorly differentiated
Table 4 Ampullary cancer cell lines reported in the literature
Cell line Primary
tumor
Cell line
derived from
Histopathology/
differentiation
TNM
stage
Kras
status
Further
characterization
Patient follow-up Reference
Cell lines successfully grown in standard culture medium
MDA-
AMP7
AMPAC Peritoneal
metastasis
Not reported rpM1 Not
reported
Aneuploidy and
structural
chromosomal
mutations
Peritoneal metastases
occurred 9 months after
resection of primary tumor
Frazier et al.
(Frazier et al.
1992)
AVC1 AMPAC Primary
tumor
Moderately differentiated,
arising from villous
ampullary adenoma
pT1N0
cM0
Mutated Tumorigenic in mice,
moderate
Gemcitabine
sensitivity
Perioperative death Sorio et al.
(Sorio et al.
2004)
RCB1280 AMPAC Liver
metastasis
not reported not
reported
Not
reported
structural
chromosomal
mutations
Not reported RCB
SNU478 AMPAC Primary
tumor
poorly differentiated with
signet ring cell features
pN0
(0/5)
Wild
type
E-Cadherin wild type
but methylated
Not reported Ku et al.
(Ku et al. 2002)
SNU869 AMPAC Primary
tumor
well differentiated with
focal papillary
differentiation
pN1
(5/10)
Wild
type
E-Cadherin wild type
and expressed
Not reported Ku et al.
(Ku et al. 2002)
Other cell lines reported
UKEAC-
99
AMPAC Primary
tumor
cell line discarded (personal communication with authors) Peiper et al.
(Peiper et al.
2003)
RCB1281 AMPAC Peritoneal
metastasis
cell line derived from same patient as RCB1280 RCB
RCB1282 AMPAC Lymph node
metastasus
RCB
Abbreviations: AMPAC ampullary adenocarcinoma, RCB RIKEN Bioresource Center Cell Bank http://cell.brc.riken.jp/en/
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marked decrease of KRT20 expression and small but
significant decrease in CDX2 expression was observed
in the intestinal-like SNU869 cells, while KRT7 and
CDX2 expression increased in the pancreatobiliary-like
SNU478 cells (Fig. 6b).
Cell growth was slightly enhanced by CAF-CM in the
mesenchymal-like cell lines except for the already fast-
growing MDA-AMP7 (Fig. 5a and b). Among the
mesenchymal-like cell lines, AVC1 was the only cell line
expressing measurable amounts of E-Cadherin. Consistent
with EMT process, both ZEB1 expression and cell
invasiveness were increased while E-Cadherin expression
decreased with CAF-CM treatment (Fig. 6c). E-Cadherin
was not expressed in the other two mesenchymal-like cell
lines, and the high basal ZEB1 expression levels increased
in RCB1280 cells but decreased in MDA-AMP7 cells.
Nevertheless, matrigel transmigration were increased in
MDA-AMP7 cells. RCB1280, as the most invasive of the
five cell lines, did not further increase its matrigel
transmigration with CAF-CM treatment (Fig. 6c). Re-
garding subtype markers among the mesenchymal-like
cells, only CDX2 was expressed to a relevant but low
degree in MDA-AMP7 cells, and further decreased
with CAF-CM treatment (Fig. 6c).
Proteomic analysis of CAF-conditioned medium effect on
ampullary cancer cells
To investigate the influence of CAF on the AMPAC
cancer cell proteome, we performed quantitative shotgun
proteomics of AMPAC cells treated with CAF-CM versus
controls under standard culture conditions, respectively.
Quantitative proteome comparison was performed for cell
lysates of all five AMPAC cell lines. Stable isotope labeling
with either 12COH2 formaldehyde (light) or
13COD2
formaldehyde (heavy) was used for relative quantitation.
LC-MS/MS analysis identified 3 258 proteins in
MDA-AMP7, 3 007 proteins in AVC1, 2 207 proteins
in RCB1280, 3 139 proteins in SNU487 and 4 376
proteins in SNU869. The fold-change values (Fc-values,
log2 of CAF-treated/untreated ratio) show a near-
normal distribution for all five replicates comparing
CAF-conditioned medium treated and non-treated cells
(Fig. 7a). These findings indicate the majority of
proteins not being affected in abundance upon cultivation
in CAF-conditioned medium. Furthermore, there is a
moderate level of correlation between the Fc-values of the
MDA-AMP7, AVC1, RCB1280 and SNU487 (Fig. 7b) in-
dicating a comparable reaction in proteome composition
of these cell lines to cultivation in CAF-conditioned
Fig. 5 Gemcitabine treatment of ampullary cancer cell lines. Cell viability was quantified by MTT assay. a baseline cell growth relative to the
fastest growing (MDA-AMP7) cells (b) cell growth in CAF-CM relative to controls (c) cell growth under low-dose Gemcitabine (40 nM) treatment
relative to PANC-1 (d) cell viability under varying concentration of Gemcitabine (100 nM, 1 μM or 10 μM) relative to untreated controls. Bar charts
depict mean and error bars standard deviation from n = 6 measurements, * p < 0.05 in two-sided t-test compared to untreated control. Abbreviations:
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, CAF-CM cancer associated fibroblast conditioned medium
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medium. Consequently, an overlap of 1 493 proteins was
identified among these four AMPAC cell lines (Fig. 7c).
Partially incomplete overlap of proteome coverage is
an intrinsic characteristic of mass spectrometry-based
proteomics [45]. On the other hand, the Fc-values of the
SNU869 cell line lack appreciable correlation to any of
the other cell lines; suggesting a different rearrangement
of proteome composition upon cultivation in CAF-
conditioned medium.
Proteins were considered as being differentially abun-
dant upon cultivation in CAF-conditioned medium if
the corresponding Fc-value (log2 of heavy:light ratio) is
either greater than 0.58 or less than -0.58, corresponding
to a change in abundance exceeding 50 %. Mass
spectrometry analysis showed that 1 184 proteins were
significantly affected in MDA-AMP7; 1 323 in AVC1;
876 in RCB1280; 1 603 in SNU487; and 745 in SNU869.
A total of 345 proteins were commonly affected in these
a
b
c
Fig. 6 Cell invasion and gene expression changes in ampullary cancer cell lines treated with CAF conditioned medium. Cell invasion was
quantified by matrigel transmigration assay and mRNA expression by real time PCR. a baseline matrigel transmigration relative to most
invasive cell line RCB1280. b effect of CAF-CM on intestinal-like cell line SNU869 and pancreatobiliary-like cell line SNU478. c effect of CAF-CM on
mesenchymal-like cell lines MDA-AMP7, AVC1 and RCB1280. Diagrams depict mean and error bars standard deviation from n = 4 measurements,
* p < 0.05 in two-sided t-test compared to untreated control. Abbreviations: AMP7 MDA-AMP7, CAF-CM cancer associated fibroblast conditioned
medium, ZEB1 zinc finger E-box binding homeobox 1, CDH1 Cadherin 1 = E-Cadherin, KRT Cytokeratin, CDX2 Caudal type homeobox 2
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four AMPAC cell lines (MDA-AMP7, AVC1, RCB1280
and SNU487) (p < 0.10, two-tailed t-test). Further 87
proteins were commonly affected in three cell lines with
adequate correlation (p < 0.10, two-tailed t-test). Collect-
ively, a total of 432 proteins were differentially affected
more than two-fold in at least three cell lines (n ≥ 3);
208 up-regulated (log2 ratio > 0.58, p < 0.10, two-tailed
t-test), and 224 down-regulated (log2 ratio > 0.58,
p < 0.10, two-tailed t-test). Additional data is listed in
Additional file 1: Tables S1 and S2.
Ingenuity pathway analysis of CAF-conditioned medium
effects on ampullary cancer cells
Ingenuity pathway analysis was used to elucidate bio-
logical themes being induced or repressed in AMPAC
cells upon cultivation in CAF-conditioned medium.
Comparison of the expression of all affected proteins (with
pre-defined log2 cut-off value at ± 0.5) revealed that
several pathways including cellular proliferation and me-
tabolism, cell death, and protein synthesis were signifi-
cantly affected (p-value < 0.01) (Fig. 8a). Hierarchical
clustering of all proteins identified in each AMPAC cell
lines, based on activation z-score, showed similar likelihood
of regulating proteins (based on a statistically significant
pattern match of up- and down-regulation of biological
processes) between the mesenchymal-like cell lines MDA-
AMP7, AVC1, RCB1280 and the pancreatobiliary-like
SNU487. In contrast, the more intestinal SNU869 showed
regulation in the opposite manner in many identified bio-
logical themes.
The twenty most relevant biological themes affecting
tumorigenesis and cancer progression of AMPAC cells
upon the treatment with fibroblast conditioned medium
are illustrated in Fig. 8b. Some of these biological pro-
cesses include (a) positive regulation in cellular growth
and proliferation, as well as infection and proliferation
of tumor cell lines; and (b) negative regulation in tumor
cell death and apoptosis. Many of these biological
networks and pathways were also identified in Gene
Ontology (GO) enrichment analysis. Gene Ontology
(GO) enrichment analysis within the AMPAC subset of
four (mesenchymal- and pancreatobiliary-like) cell lines
(MDA-AMP7, AVC1, RCB1280 and SNU487) showed that
208 up-regulated proteins were mainly enriched in mRNA
metabolism, intracellular transport and activation of the
cytoskeleton (Table 5). STRING protein-protein interac-
tions and KEGG pathway enrichment analyses showed the
majority of these proteins being involved in cellular motil-
ity, RNA transport and organization of ribosomal proteins
(Fig. 9a). For SNU869, a total of 432 up-regulated proteins
were mostly enriched in membrane and cellular component
organization, as well as in metabolic processes (Table 6).
For down-regulated proteins within the same subset
of the four cell lines, GO enrichment analysis showed
Fig. 7 Distribution of identified proteins in AMPAC cells cultivated in CAF conditioned medium. a Geometric mean (horizontal bar) of fold
change values (log2 of CAF-treated/control) of proteins from each AMPAC cell line comparing the CAF conditioned medium treatment or control.
b Fold change correlation of all quantified proteins between different AMPAC cell lines treated with CAF-conditioned medium. c Venn diagram
showing the overlap of proteins identified in individual AMPAC cell line upon cultivation with CAF conditioned medium or control
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that the 224 proteins were mainly involved in
metabolic processes and phosphorylation (Table 5).
STRING analysis and KEGG pathway enrichment ana-
lyses grouped these proteins into two main clusters;
oxidative metabolism and phosphorylation, and amino
acid and lipid metabolism (Fig. 9b). On contrary, 314
proteins were down-regulated in SNU869, which
mainly involved in protein translation and peptide
biosynthetic processes (Table 6).
Discussion
AMPAC is a relatively rare tumor comprising about
15–20 % of all adenocarcinomas resected by pancrea-
toduodenectomy [6, 46–48]. The most important
prognostic factors reported in the literature include
surgical margin, lymph node metastasis and intestinal
differentiation. The latter has been highlighted as a de-
cisive parameter for clinical prognosis. Its tumor biology
is less aggressive and postulated to be more related to
colorectal cancer [49]. Therefore, suggested analogous
therapy such as liver metastasis resection as well as
chemotherapy regimens used for colorectal cancer might
be indicative for intestinal AMPAC [50–52]. Despite the
growing number of cell lines and increasing relevance
of cell line based high-throughput screening methods
[21, 22], establishment of ampullary cancer cell lines
has only been limited [23–26]. Moreover, in vitro ex-
perimental data on AMPAC is absent. Hence, our aim
Fig. 8 Bioinformatics analysis of quantified proteins by ingenuity pathway analysis. a Patho-physiological pathways and processes of proteins
from AMPAC cell lines following treatment with CAF-conditioned medium or control. The threshold denotes statistical significance at p < 0.01.
b Hierarchical clustering based on activation z-score, showing likelihood of regulating proteins based on a statistically significant pattern match of
up- and down-regulation of biological processes
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is to establish an experimental platform for the study
of AMPAC biology.
Clinical data from patients treated at our center con-
firmed that intestinal subtype is a main prognostic factor
and was significantly associated with KRT 20 and CDX2
expression and KRT7 negativity. A novel aspect was a
significant association between intestinal differentiation
and reduced features of EMT (tumor budding, ZEB1
and E-Cadherin expression). We were able to obtain and
grow one cell line from each of the five reported patients
(a total five AMPAC cell lines) under the same standard
culture conditions. Basic characterization on the basis of
markers for subtype and EMT revealed remarkable
heterogeneity among these cell lines. However, hierarch-
ical clustering analyses combining tumors and cell lines
based on expression pattern suggested three main pat-
tern: mesenchymal-like, PB, and INT differentiation.
Interestingly, these observations also reflect the origin of
the cell lines: two out of the three mesenchymal-like cell
lines were isolated from metastases, where theoretically
increased EMT features would be postulated. The AVC1
cells were derived from a moderately differentiated
primary tumor, but displayed a loss of differentiation
markers and partial EMT. The pancreatobiliary-like cell
line SNU478 was derived from an AMPAC with signet
ring cell features, which is a rare and aggressive tumor
[53]. Loss of E-Cadherin by germline mutation is
associated with diffuse gastric adenocarcinoma with sig-
net ring cells [54]. Similarly, SNU478 has been shown to
have the CDH1 gene repressed by DNA methylation
[24] and displayed similarly high invasiveness as the
mesenchymal-like cells.
Among the five cell lines, only one intestinal-like cell
line (SNU869) was found, which is not surprising given
that it was previously suggested that only the most
aggressive tumor cells can be grown as cell lines in
standard culture conditions [55]. Notably, SNU869 is the
only cell line reported to be derived from a well-
differentiated primary AMPAC tumor. SNU869 cells
displayed a markedly reduced growth and invasiveness
compared to the other cell lines, as would be expected
from clinical correlation. Interestingly, this intestinal-like
cell line was not sensitive to low concentration of
Gemcitabine, a drug often used to treat ampullary cancer.
This is consistent with current clinical reports suggesting
poor response or even reduced survival with Gemcitabine-
based chemotherapy in intestinal type AMPAC [44, 56, 57].
Cancer associated fibroblasts (CAF) are known to
promote tumorigenesis, invasion and metastasis [58, 59].
Additionally, the prognostic value of CAF’s immuno-
histochemical markers as well as stromal gene expression
profiles have been previously reported [60–63]. However
there is currently no standardized grading system to look
at stromal CAF activity [63]. Here, we adopted a simple
stromal grading system relying on morphological features
of CAF [28] and noted increased CAF activation and
EMT features in non-intestinal AMPAC. Therefore we
tested the hypothesis in which CAF could enhance growth
and induce EMT and a phenotypic shift in AMPAC cells
through CAF secreted factors.
Treatment of AMPAC cells with CAF-CM from CAF
isolated from a human AMPAC had several effects. In
general, cellular growth and invasion were increased,
ZEB1 expression increased and/or E-Cadherin expres-
sion decreased in the cell lines where these genes were
expressed. With regard to AMPAC subtype marker
expression, decrease of the intestinal markers KRT20
and CDX2 were observed. The cell line derived from
signet ring cell AMPAC (SNU478) however displayed
decreased cellular invasion, and increased CDX2 and
KRT7 genes expression. The undifferentiated MDA-
AMP7 cell line showed a slight decrease compared to
the very high ZEB1 baseline expression. These findings
finding in which CAF-conditioned medium enhanced
AMPAC cell growth and EMT features while suppress-
ing intestinal markers and increasing KRT7 are well
correlated with clinical data from histopathology and
patient survival. It is also known that some cancer cell
lines display a loss of differentiation markers and E-
Cadherin in standard culture [62, 64, 65]. However these
features were not observed in the five cell lines.
Table 5 Gene Ontology (GO) functional enrichment analysis
regulated proteins in ampullary cancer cells MDA-AMP7, AVC1,
RCB1280 and SNU487
GO terms of up-regulated proteins Count FDR
GO:0065007 Biological regulation 93 1.41E-02
GO:0071840 Cellular component
organization or biogenesis
67 2.08E-06
GO:0051179 Localization 54 5.18E-04
GO:0016071 mRNA metabolic process 42 9.87E-23
GO:0032268 Regulation of cellular
protein metabolic process
44 5.73E-11
GO:0050896 Response to stimulus 75 1.09E-02
GO terms of down-regulated proteins Count FDR
GO:0008152 Metabolic process 98 9.97E-04
GO:0009987 Cellular process 119 3.15E-03
GO:0044237 Cellular metabolic process 113 4.87E-11
GO:0009117 Nucleotide metabolic process 37 2.96E-12
GO:0016310 Phosphorylation 22 2.60E-03
GO:0006629 Lipid metabolic process 24 5.66E-04
Enrichment is analyzed using all differentially expressed proteins with fold-
change of greater than 50 % in MDA-AMP7, AVC1, RCB1280 and SNU487 cells
cultivated in CAF-conditioned medium versus non-treated control cells (log2
ratio of > 0.58, p-value < 0.1, two-tailed t-test, FDR < 0.05)
Abbreviations: CAF cancer associated fibroblast, FDR false discovery rate
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Proteomic analysis revealed parallel regulation shifts in
the mesenchymal- and pancreatobiliary-like cell lines.
Pathophysiological pathways of cellular proliferation and
survival, activation of the cytoskeleton and intracellular
transport were up-regulated, whereas pathways of cell
apoptosis, protein translation, oxidative, amino acid and
lipid metabolism were down-regulated. These findings
suggest a supportive role of CAF in AMPAC cell survival,
proliferation and motility. Of note, the intestinal-like cell
line SNU869 showed many of these regulation processes to
respond in an opposite manner, suggesting CAF response
to be differentiation-dependent in AMPAC. In addition,
KRT20, CDX 2, KRT 7, ZEB 1 and CDH 1 were not
consistently identified in all the cell lines (Additional file 1:
Table S1, complete mass spectrometry data available via
ProteomeXchange with identifier PXD002657). This is not
surprising, as undersampling and partially incomplete
overlap of proteome coverage is an intrinsic characteristic
of mass-spectrometry based studies [45].
A major drawback of this study is that classification of
cell lines relies on in vitro parameters and correlation
with an independent clinical dataset from tumors. How-
ever, no information on the subtype of the tumors that
the cell lines were derived from, nor patient follow-up, is
available for validation of conclusions drawn. Up to
now, this remains a general problem of virtually all
standard cancer cell lines. Even the most advanced large
scale cell line panel characterization studies have not
a
b
Fig. 9 Network visualization of differentially regulated proteins by STRING in AMPAC cells upon cultivation with CAF conditioned medium. Clustering
of proteins were based on KEGG pathway for (a) up-regulated proteins in at least 3 cell lines (Fc > 0.58, p≤ 0.1), and (b) down-regulated proteins in at
least 3 cell lines (Fc < -0.58, p≤ 0.1)
Lai et al. BMC Cancer  (2016) 16:195 Page 14 of 17
been validated using this approach [19–22]. Neverthe-
less, these studies suggest that cell lines do reflect im-
portant aspects of the clinical tumor biology, like marker
expression and drug sensitivity.
Conclusions
On the basis of clustering for EMT features and subtype
marker expression, most of the available AMPAC cell
lines seem to reflect a poorly differentiated pancreato-
biliary or mesenchymal-like phenotype, which is consist-
ent with their state of origin from moderate to poorly
differentiated primary tumors or metastases. Only
SNU869, which is derived from a well-differentiated
primary tumor, displays an intestinal phenotype and
characteristically segregated from the other cell lines
specifically in basic marker expression, drug sensitivity
as well as proteomic CAF-response. Based on these
findings, we therefore suggest that SNU869 is presently
the most appropriate cell-based model for intestinal-like
AMPAC, while others seem to reflect aggressive and
metastatic AMPAC subtypes.
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